Developpment of small molecules to prolong the protective effect of the Integrated Stress Response InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class CD31xITAM bispecific antibodies for targeted immune modulation Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases. The company’s lead program is a first-in-class CD31×GPVI bispecific antibody being developed for the treatment of thromboinflammatory diseases. This novel approach provides both antithrombotic and anti-inflammatory efficacy while minimizing bleeding risk, thereby addressing major critical medical unmet needs in the field. Our company is financed by leading European investors and led by an experienced management team. Santé, Healthcare, …

203 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering personalized medicine in epigenetics Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey. The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented …

86 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering Next-Generation Stroke Treatments 👉Funding round is still open: https://capitalcell.com/campaign/freeox/ FreeOx Biotech: Advancing Stroke Care through Innovation and Precision Medicine FreeOx Biotech is a pioneering late-stage clinical biotechnology company dedicated to transforming acute ischemic stroke (AIS) management. Our mission is to improve outcomes for stroke patients through the discovery and development of Cerebrovascular Protective Therapeutics. Our lead asset, Ox-01, is a Phase 3-ready investigational drug with breakthrough potential as an emergency adjunct therapy to Mechanical Thrombectomy. Selected by the prestigious StrokeNet Thrombectomy Endovascular Platform (STEP) program, funded by the National Institute of Neurological Disorders and Stroke (NINDS), Ox-01 represents a …

63 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Targeting Glial Cells and Brain Metabolism to Treat Neurological Diseases GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells, the 'support cells'​ of neurons, to sustain and enhance brain metabolism in pathological conditions. Our vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.

67 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

A clinical-stage biopharma discovering and developing novel treatments for the most troublesome symptoms of Parkinson's. IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam. IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mapping the druggable transcriptome An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Neuroscience Solutions MODAG focuses on research and development of therapeutics and diagnostics for neurodegenerative diseases. It is a privately held company located at the Hochtechnologiepark Wendelsheim, Germany with additional Research & Development facilities in Munich and Göttingen. MODAG’s innovative approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders. MODAG ́s collaborations with top-tier US and European research institutions, combined with the interdisciplinary research and development expertise of the founder ́s and the management team, provide ideal conditions for the accelerated implementation into clinical applications. Built upon an extensive portfolio of patented active compounds, …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A preclinical-stage drug-development company specialized in neuro-oncology GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year. To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs. GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights. GlioCure's team has the experience and the know-how to ensure the successful completion of GC01’s development plan: Louis-Marie is a biotech entrepreneur with 15 years of experience …

59 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Transcribing For Better Lives Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAheadTM, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Group's GalAheadTM mxRNA technology, is currently in Phase I development. STP125G is the second siRNA therapeutics …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Clinical stage fibrosis and cancer treatments Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering the future of aging medicine. We are advancing small molecule therapeutics for age-related diseases. Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space. At its core are our ultra-large, in-house aging datasets, which provide a rich foundation for target identification and therapeutic discovery. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, rejuvenation, molecular biology, novel therapeutics, therapeutics, and small molecules

178 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Scale drug discovery with quantum-inspired physics and generative AI AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA …

64 similar entities Tags: FrenchTech120 Type: Startup Activities: deeptech healthtech Technologies: A.I. Generative A.I. Synthetic Biology

Science of certainty Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future. Founded in 2008, Gubra has grown from a metabolic research specialist into a diversified organization of more than 300 scientists and experts. Today, we advance proprietary therapeutic programs, deliver high-end preclinical research services to global partners, and create new drug discovery opportunities through agile …

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Delta4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta4 is driving the forefront of digital drug discovery and development. We leverage a proprietary computational analytics platform "Hyper-C", combining straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects. drug repositioning, drug discovery, compounds, orphan diseases, indication expansion, AI, and omics

178 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered …

209 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating Assessment of Novel CNS Therapies with Real World Objective Data We’re developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. This addresses the significant unmet need for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience.

63 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology Data Analytics

Navigating Biology, Discovering Drugs Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. We use the models to simulate biological processes in order to identify viable drug targets and discover new biology. The company is building a pipeline of first-in-class drug discovery programmes based on the identified targets.

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

Targeting Transglutaminase for Research & Medicine! ZED1227 First Tissue Transglutaminase Inhibitor in Clinical Trials! Zedira is specialist and global brand for transglutaminase. More than 200 specialty reagents for transglutaminase-related R&D. Researchers from academia and industry (including 12 of the top 15 big pharma companies) benefit from Zedira’s cutting edge products – and in an increasing manner – from customised services. Solutions for site specific labeling of proteins using transglutaminases form Zedira’s latest product field. Simply - "The Transglutaminase Company" and From bench to bedside

59 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Pioneering drug discovery company exploiting cutting edge technologies to create best-in-class small molecule medicines C4XD is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‐leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD …

295 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines with Generative AI. Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics. Our proprietary platform, MAUD 1.0, enables the rapid creation of macrocycles with drug-like properties such as oral bioavailability and cell permeability. We partner with top-10 pharma leaders (e.g., Bristol Myers Squibb) to accelerate preclinical discovery, and we are backed by world-class investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.

66 similar entities Type: Startup Activities: deeptech Technologies: A.I. A.I. - Machine Learning Generative A.I. Synthetic Biology

An industry-academia partnership using human genomics data for systematic drug target identification and prioritisation. Developing new medicines is hard: 9 out of 10 times, clinical drug development fails. Open Targets exists to improve this. We are a pre-competitive public-private partnership—bringing together EMBL-EBI, Genentech, GSK, MSD, Pfizer, Sanofi, and the Wellcome Sanger Institute—to systematically identify and prioritise targets for the development of new therapies. Our partners work together to design and implement projects combining large-scale experimental research with world-class computational science. Our projects build evidence that connects genes to diseases, and we share our results openly. Our freely available Open Targets …

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Late clinical stage company focused on drug discovery and development for the treatments of rare disorders of the CNS For additional information: info@sombiotech.com Pre-clinical validation, Licensing, In silico screening, Rare Diseases, Drug repurposing, Orphan CNS indications, Central Nervous System, Intellectual Property, and Artificial Intelligence

288 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: A.I. Synthetic Biology

elegant software that guides successful drug discovery Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDropTM, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDropTM enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company’s new Augmented ChemistryTM products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics A.I.

#insilicomeds, #drugdiscovery, #ai, #oncology, #RL, #DL #aging, #longevity #biologics #LLMS #AIDD Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. artificial intelligence, deep learning, reinforcement …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning Generative A.I. Synthetic Biology

Accelerating Assessment of Novel CNS Therapies with Real World Objective Data We’re developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. This addresses the significant unmet need for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience.

68 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology Data Analytics

Collaborative intelligence to power your pipeline At DaltonTx, we are redefining how technology powers drug discovery — creating the intelligence engine behind tomorrow’s medicines. Our adaptive, AI-enabled platforms give pharma, biotech, and CROs the intelligence backbone modern R&D cannot move forward without. Purpose-built for small molecules and biologics, our technology integrates seamlessly into scientific workflows, learns from every experiment, and accelerates the path from idea to medicine. Unlike traditional project-based models, DaltonTx provides lasting capability: collaborative systems that combine machine learning, software engineering, and deep drug discovery expertise. The result is technology that learns from every scientist, model, and experiment …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and …

402 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

Engineering Hope MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

VarmX is a young biotech company focusing on the development of therapies in the field of hemostasis and thrombosis. VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in …

76 similar entities Type: Startup Activities: manufacturing deeptech biotech healthtech Technologies: Synthetic Biology

Our mission is to make a difference in the lives of individuals suffering from neurodevelopmental, cognitive disorders. IAMA Therapeutics is a clinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders. The Company’s lead candidate, IAMA-6, is a "best-in-class" selective NKCC1 inhibitor being developed for various orphan brain disorders, including drug-resistant epilepsy, and started the Phase 1 clinical trial in January 2024. Other pipeline candidates include new molecular entities to target Cation Chloride Cotransporters in pediatric neuropsychiatric conditions.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

www.aukera-tx.com Aukera Therapeutics is a spin-off from the Biozentrum at the University of Basel, developing the first RAPTOR inhibitors for the treatment of mTORC1-related pathologies. We pair deep mTOR expertise with an AI-driven drug discovery engine built for complex and hard-to-drug targets. Our lead program focuses on rare neurological disorders such as Tuberous Sclerosis. Future applications of RAPTOR inhibitors include neurodegenerative, metabolic, and age-related diseases.

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Allosteric modulators for Human Health Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial …

59 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A study involving the LPSM unveils the mechanism of the human flippase ATP8B1 autoinhibition, as well as its regulation by lipids and phosphorylation. The study provides a better understanding of the impact of flippase mutations responsible for intrahepatic cholestasis on its enzymatic activity.

53 similar entities Type: Startup Activities: deeptech

AI and Nature in Perfect Synergy MeNow is an AI-driven discovery company focused on developing novel natural bioactive compounds for FOOD, COSMETICS & HEALTH. We integrate advanced probabilistic AI, systems biology, and molecular science to identify and validate new bioactives with strong efficacy, safety, and scalability profiles. Through this approach, MeNow has achieved a breakthrough in longevity-relevant biology, generating proprietary intellectual property around key pathways such as SIRT1 activation, heparanase modulation, and GLP-1–associated mechanisms, with applications across metabolic health, inflammation, tissue function, and healthspan support. Our work bridges fundamental biology and real-world applications, enabling the translation of advanced discoveries into …

89 similar entities Type: Startup Activities: deeptech Technologies: A.I.

Applying machine learning in drug development Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making. We currently work …

200 similar entities Type: Startup Activities: biotech Technologies: A.I. A.I. - Machine Learning Data Analytics

MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe. The Company considers its employees to be its most valuable asset and we are committed to providing opportunities for individuals to learn and grow as a means to further their professional development. MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees …

258 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

ENABLING TECHNOLOGY FOR THERAPEUTICS TARGETING MEMBRANE PROTEINS G.CLIPS biotech created the first enabling technology to unravel the potential of drug and antibody candidates on pathology-like format membrane proteins to be used in screening efforts, characterization, structural studies, mechanism of action, pharmacological profiling and target validation. We offer a unique technology to express, stabilize, select and validate membrane proteins as targets based on proprietary G.Screen® Platform. G.Mixes® G.Select® Assay G.Lipidomics® G.Validation® Assay We provide tailor-made services to pharma, biotech and animal health companies targeting membrane proteins (GPCRS, Receptors, Transmebrane Proteins) that would like to ascertain the necessary environment and conformation stabilization …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AlgoTx develops novel therapeutic solutions for complex pain AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making …

182 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A unique and innovative technology platform for next-generation oligonucleotide therapeutics NAXIA Discovery (formerly IASO Discovery) is a TechBio company developing a chemistry-driven oligonucleotide discovery platform applicable across multiple therapeutic areas. Built as a spin-off from over 20 years of academic and translational research, NAXIA combines deep expertise in oligonucleotide chemistry with a proprietary discovery platform spanning design, synthesis, conjugation, and formulation. NAXIA Discovery operates an open and collaborative platform, partnering with academic institutions, biotechs, and industry players through services, co-development, licensing, and spin-off creation. A core technology enabled by the platform is a first-in-class synthetic G-quadruplex approach that introduces a …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sharp understanding of the hardest things At Sagacity Health, we discover new horizons in oncology by merging Agentic AI with Biotech to decode the secret world inside tumors - turning unseen ecosystems into the next frontier of precision therapeutics. Our main objective is to bridge groundbreaking science, clinical partnerships, and industrial-scale innovation to bring first-in-class therapies from lab to patient. This is not just drug development; it is a paradigm shift in how we fight cancer.

265 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Neuroprotecting Patient's Future Saxol, newborn company develops innovative compounds able to fight and/or to prevent peripheral neuropathies, including Diabetes peripheral neuropathies, Immuno and Chemotherapy-Induced Peripheral Neuropathies (CIPN). Based on IAB research on Carbazole structure (Lafanechère Team) and with the support of Linksium, we plan to bring to patients, new neuroprotective drugs to answers current Unmet Medical needs CARBA1, our lead compound has neuroprotective activity through a mechanism of regulation and reactivation of energy production at the cellular level. We plan first to develop Carba1 for CIPN Unmet Medical Need and to enlarge after to Diabetes Peripheral Neuropathy DPN and other …

98 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking New Immunotherapy Paths with Smart Peptides SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology. SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most. SPIMA Therapeutics is part of the nexus of Landmark Bioventures. Join us in shaping the future of medicine, where discovery meets dedication. Immunothery

85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AI for digital twin of cells DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, …

294 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning SaaS

Human PK data from preclinical stages BrainPlotting is a french contract research organization company which offers his knowledge to predict the entrance of drugs into the brain To that end BrainPlotting developped in vitro models based on fresh human tissus and cells. BrainPlotting is incubated at the Brain and Spine Institute (ICM), Paris, France Our core business is the study of pharmacokinetics (PK) in the human brain. The molecules that we study can have CNS targets as well as peripheral targets. To study the brain's PK, BrainPlotting uses the most accurate predictive models and the most recent methods and tools. …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Artificial intelligence for new drug design We are a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms MakyaTM for generative drug design and SpayaTM for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and …

59 similar entities Tags: FrenchTech2030 Type: Startup Activities: deeptech biotech it services Technologies: A.I. - Deep Learning A.I. A.I. - Machine Learning Generative A.I.

Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle

281 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology

Turbine is virtualizing biological experiments with AI to accelerate drug discovery & enhance clinical translatability. Turbine is virtualizing biological experiments with AI to accelerate drug discovery and enhance clinical translatability. We’ve spent the last decade building virtual disease models designed to ultimately become second only to the patient in predicting drug response. By simulating how cells and tissues behave under treatment, Turbine helps pharma identify the right therapeutic ideas smarter and faster, cutting years of dead-end research and reducing Phase II failure caused by poor efficacy. Scientists can now run billions of virtual experiments to uncover risk, design smarter trials, …

75 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our goal at Venomtech is to lead the way towards an era where venom-based research tools are routinely used as sources Venomtech targeted arrays provide a unique opportunity to identify novel screening tools and discover novel therapeutics. Animal venoms are a complex mix of peptides, small molecules and proteins that bind, activate, inhibit or otherwise modulate molecular targets such as ion channels, GPCRs and kinases. Screening crude venoms to identify bioactive components is made extremely difficult by a large number of potentially conflicting activities (e.g. cytotoxins masking pharmacology) and de-convolution challenges. In the past, these challenges have hampered many of …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking new therapeutic pathways for metabolic health Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our …

222 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Amplio Pharma is a novel and exciting product company developing improved versions of already great drugs. Amplio Pharma is a novel and exciting product company developing improved versions of already great drugs. Amplio Pharma is a privately owned wholly women founded pharmaceutical company. Our vision is to develop and apply modern-day technology to fix the short-comings from drugs that otherwise have a proven track record in their disease area. Our first development candidate, NovoBioJect (AMP101), is being developed to boost the responder rate to current 1st line RA treatment from ca 35% to up to 70%. We intend to reach …

120 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leveraging the power of physics-driven generative AI to unlock new therapeutic opportunities against undruggable targets At NEBULA, we revolutionize drug discovery by providing a comprehensive, physics-based dataset-free genAI solution for mapping the full range of therapeutic target conformations. Unlike traditional drug development focused on small molecule screening, our innovative approach delves deep into the dynamic nature of macromolecular targets—proteins, mRNA, antigens—unveiling their multitude of physiological conformations. Our dataset-free technology integrates generative genAI with molecular dynamics, rooted in physical principles, to generate an exhaustive profile of potential target structures without relying on pre-existing data. By enhancing the understanding of drug targets, …

89 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. Generative A.I.

NEW FRONTIERS IN NEUROSCIENCE Neurentis PLC is a late-clinical stage UK specialty pharma company, focusing on neuroscience and specialising in the development of novel treatments for mental health and other neurological and psychiatric diseases. Our product pipeline is balanced with an advanced lead drug for the treatment of Treatment-Resistant Depression (TRD) in the last stages of drug development as well as earlier stage drug candidates in collaboration with research institutions and other companies. The company is run by experienced ex-pharma industry executives, with more than 35 years’ experience in the sector each. The company’s low-risk commercial strategy is to commercialize …

382 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

284 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

TREVENTISTM Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology …

78 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

AI-native pharmaceutical company We are an AI-native pharmaceutical company transforming scientific innovation from Africa and the UK into high-impact global health solutions. By combining cutting-edge artificial intelligence with regional biomedical expertise, we accelerate drug discovery and development—turning underutilized insights into scalable therapeutic assets. Our mission is to close the innovation gap, reduce R&D timelines, and deliver next-generation treatments to patients worldwide.

184 similar entities Type: Startup Activities: biotech healthtech Technologies: A.I.

Innovating a New Class of Medicines to Drug the Undruggable InFocus Therapeutics is an AI-driven drug discovery company pioneering best-in-class RNA-targeting molecular glues to unlock new chemical space for transcriptional modulation and address diseases with high unmet need. Powered by a scalable, tech-enabled discovery engine, we are advancing a diversified pipeline across oncology and neuromuscular indications, with multiple programs progressing toward preclinical proof-of-concept. With a world-class founding team, strong IP, and multi-billion-dollar market potential across indications, InFocus is positioned to deliver transformative patient outcomes and sustainable value creation.

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AI- and physics-driven discovery of brain-penetrant therapeutics for age-related neurological diseases. PURR.AI develops a modular, AI- and physics-driven platform for early-stage neurotherapeutic discovery. AGELESS combines curated multimodal biological data, molecular modelling and simulation, predictive and generative AI, blood–brain barrier penetration prediction and early safety profiling to identify and optimize brain-penetrant therapeutics. A key differentiator is our proprietary generative language model for peptide design. By learning context-dependent relationships across sequences and representing both canonical and non-canonical amino acids, it can generate chemically diverse candidates beyond the natural peptide repertoire. These candidates can then be prioritized against target therapeutic profiles. Our biologically …

61 similar entities Type: Startup Activities: deeptech Technologies: A.I.

Targeting Ultra-Rapid, Durable Remissions In Depression (NASDAQ: GHRS) GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

59 similar entities Type: Startup Activities: deeptech

Extem Bioscience has been developing advanced technologies for the use of regenerative medicines and is expanding our offerings. We have identified 3 key areas that will undergo drastic shifts over the next 10 years and are in need of a multidisciplinary evidence based approach. By collaborating and co-developing with leading institutions within North America we see a brighter, healthier and trans formative future.

60 similar entities Type: Startup Activities: biotech deeptech

Pelago Bioscience At Pelago Bioscience, we’re here to help you make faster, better-informed decisions in drug discovery. In 2010, our founders began to develop our proprietary CETSA® (Cellular Thermal Shift Assay) technology, publishing a seminal research paper in Science 2013. Since then, Pelago Bioscience has become the leading CRO providing actionable, biologically relevant insights at the pre-clinical stage.Unlike traditional methods, CETSA gives you a reliable picture of drug-target interactions, ensuring that what you see in cells translates to patients. Our services rest on four pillars: • Certainty in Biological Relevance: CETSA’s physiological approach helps minimize late-stage risks. • Fast & …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

225 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision Gene Editing Applied to Small Molecule Drug Discovery Light Horse is leading the way in precision genome editing applied to small molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that play critical roles in disease biology. The high-throughput discovery platform systematically interrogates complex signaling pathways to uncover unique sites of vulnerability. Light Horse interrogates these targets in their native, cellular context to best ensure that discoveries in the lab translate into the clinic. www.lighthorsetx.com

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building the Future of Precision Medicines through V-Body, RNA and In Vivo Cell Engineering Platforms. At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement. Our approach integrates innovative target identification using advanced predictive models, antibody …

227 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Nova has built jinkō, a unique in silico clinical trial simulation platform to de-risk and accelerate clinical trials Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New therapies for neurodegenerative diseases Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Functional Receptor Screening Platform & Database - Inspired by the Extraordinary Sensing Capabilities of Insects InsectSense is a deeptech start-up and has a vision to be frontrunner in developing disruptive innovations inspired by insects that create positive societal and environmental impact. Our flagship technology, ReceptomiX, inspired by insect antennae, uses living biosensors to gather real-time activity data from hundreds of receptors (GPCRs and ion channels) simultaneously. ReceptomiX delivers fast, cost-effective, and data-driven insights into how single compounds and complex formulations interact with human biology for taste and health-related applications. With ReceptomiX, we are also building the world's most comprehensive and …

59 similar entities Type: Startup Activities: deeptech Technologies: A.I.

Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such …

204 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pyramid studio embodies an unique way of leading therapeutic innovation to fuel the pipeline of pharmaceutical companies Pyramid Studio is a First-of-its-Kind venture builder dedicated to fuel the pipeline of pharmaceutical companies Pyramid Studio embodies a new way of leading therapeutic innovation through a unique build-to-buy model. Our mission is to bridge the gap for pharmaceutical companies seeking access to breakthrough innovations and delivering new therapies to patients. In practice, our team identifies and rigorously selects groundbreaking innovations from top academic teams across Europe. We collaborate closely with our Pharma partners to co-develop and co-finance these programs, ultimately delivering IND-ready …

293 similar entities Type: Incubators & VCs Startup Activities: deeptech biotech Technologies: Synthetic Biology

Translating genetic discoveries into safe and effective treatments. Arctic Therapeutics is a clinical-stage biopharmaceutical company on a mission to treat and even prevent some of the world’s most pressing diseases by utilizing genetic sequencing to analyze and map the genetic causes of diseases at a granular level, applying our findings to develop effective treatments. Our company was founded by Dr. Hakon Hakonarson in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), which he launched in 2006 and established it as the largest pediatric biobank and genomic database in the world. We maintain close research relationships with …

368 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Decoding Metabolic Health with Explainable AI At MedInsights, we are dedicated to bringing optimized therapeutic options for patients suffering from metabolic, cardiometabolic, neurometabolic and rare diseases with high unmet needs. Our internal drug repositioning engine, NexusRx, serves as a cornerstone for our discovery research, employing internal sets of proprietary algorithms to detect unknown and unforeseen relationships between disease-targets-drugs. This opens up preclinical validation opportunities which we perform in close partnerships with our academic collaborators. We envision to perform clinical trials and bring therapeutics from lab to bed side. Crunchbase profile: https://www.crunchbase.com/organization/medinsights-0569 Biotech, Data Science, Healthcare, Computer Vision, Generative AI, Network …

525 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Data Analytics

Meddenovo offers a unique blend of AI technologies and molecular modeling to design cyclic peptide therapeutics. Meddenovo is advancing AI-driven drug discovery with a specialized technology platform designed specifically for cyclic peptides. Our platform can design cyclic peptides from scratch, even without prior experimental data, and incorporates cutting-edge technology to capture their chameleon-like properties, including cell permeability. This unique capability enables us to address previously undruggable targets with precision. Cyclic peptides are a transformative class of compounds in pharmaceutical research, offering the advantages of both small molecules and large biologics, such as exceptional binding affinities, stability, and specificity. Technological advancements …

71 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

337 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, …

92 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

THE HOME OF AI AND MULTI-OMICS At Guilford Street Laboratories (GSL), a UCL spin-out, we are dedicated to helping our clients achieve their research objectives. Leveraging machine learning-driven mass spectrometry, we deliver highly precise and sensitive biomarker panels, specializing in the analysis of protein, lipid, and metabolite markers. Whether your focus is on early disease diagnosis, drug discovery, collaboration as a partner in an EU Horizon consortium, clinical trials, or personalized medicine, our team is here to help. Mass Spectrometry, Biomarker, CRO, and Rare Disease

204 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. - Machine Learning Data Analytics

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

390 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing Precision Medicine to patients with Neurodevelopmental Disorders, including Autism Spectrum Disorder STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. Substance Use Disorder research: …

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Visionary science for life-changing cures. AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leader in applying causal Al and Gemini Digital Twins to build the deep biological knowledge that transforms drug R&D Aitia is the leader in leveraging the convergence of patient multiomic and outcome data, high-performance computing, and causal learning and AI to reveal the deeply complex circuitry of human biology to identify novel targets driving disease and focused patient recruitment for clinical development. With this new knowledge, which we capture in our Gemini Digital Twins (computational representatives) of human disease, we work with pharmaceutical partners to apply our discoveries to the next generation of breakthrough therapies. Data Analytics, Bioinformatics, Genomics Data, …

71 similar entities Type: SMB Activities: deeptech biotech Technologies: A.I. Data Analytics Generative A.I.

Using human genetics to transform cancer outcomes Pathios Therapeutics are world-leading experts with unique expertise in GPCR drug development, focused on GPR65 as a high-value immunology target with robust genetic links to multiple human diseases. Our clinical-stage oncology programme leverages cutting-edge proprietary genetic insights, transcriptomics, and functional immunology of GPR65 as a key immune cell sensor of acidosis in multiple pathological environments, to bring about a revolutionary new approach to treating a broad spectrum of cancers. We are also building an emerging pipeline in neuroinflammatory and neurodegenerative disorders leveraging the broader immunological roles of this receptor in cell types such …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The First Cell-Centered Computational Model of Human Disease CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain …

91 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

We generate preclinical data that accelerates drug development. Modern research without blindspots, through a solution that unveils important insights in preclinical trials. Biotechnology , Drug development, Machine learning, Artificial Intelligence, Deep tech, Preclinical research, Animal welfare, and 3R

117 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing a pipeline of first-in-class oral small molecule mPTP inhibitors as treatments for neurodegenerative diseases NRG Therapeutics is a clinical stage neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) and Parkinson’s. The company’s pipeline of first-in-class small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action. Inhibition of the mPTP has been shown to protect neurons, reduce neuroinflammation, and improve motor function in preclinical disease models. …

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A drug-discovery company focused on oncology, with a unique and powerful combination of expertise that sets us apart. Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology A.I. - Machine Learning A.I.

Harnessing the power of RNA modification STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your local champion and alternative partner Newbury Pharmaceuticals was founded in 2020 by Swedish Karl Karlsson. We are rapidly growing and offer a product portfolio of specialty pharma medicines with focus on the Scandinavian markets. The portfolio strategy includes niche and value-added small molecules, products based on peptide technology as well as biosimilars in a variety of therapeutic categories. The portfolio consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology representing more than 70 percent. The company was listed on Nasdaq First North, February 2022.

98 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Empowering Discovery: Precision Insights for Safer Drug Targets. Prevent target safety failures with unique data insights and cutting-edge approaches. ‍ Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities. Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Data Analytics A.I. Synthetic Biology

Development of covalent small molecules to transform the treatment of autoimmune and inflammatory disorders ARTICA Therapeutics and its seasoned team started operatons in 2020 and was supported by pre-Seed financing from BioGeneration Ventures. Artica is dedicated to developing novel small molecule medicines for inflammatory and autoimmune indicatons. Artca is at the forefront of covalent binding technology as well as in label-free cellular-based screening approaches. The unique combinaton of these capabilities allows rapid progression of the best drug candidates that have unprecedented and superior characteristics, creating novel and highly selective therapies for patients with unmet medical need.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Evaluate your most effective drug candidates in vivo using objective & translational measurements in the brain. #EEG SynapCell is a Brain-focused biotechnology company that provides drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models, following clinical-like protocols. Our capabilities include dose-response studies, pharmacodynamics, biomarker identification and modulation, disease-modifying assays, model phenotyping, as well as phenotypic screening for lead selection and validation. Our expertise in Neuroscience covers Epilepsy, Parkinson's disease, Essential Tremors as well as information processing defects such as …

126 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology